Calamos Advisors LLC Sells 2,100 Shares of MetLife, Inc. (NYSE:MET) (2024)

Calamos Advisors LLC decreased its position in shares of MetLife, Inc. (NYSE:MET – Free Report) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,712 shares of the financial services provider’s stock after selling 2,100 shares during the period. Calamos Advisors LLC’s holdings in MetLife were worth $10,628,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. FWL Investment Management LLC bought a new position in MetLife during the 4th quarter worth $26,000. Studio Investment Management LLC bought a new position in MetLife during the 4th quarter worth $29,000. Planned Solutions Inc. bought a new position in MetLife during the 4th quarter worth $28,000. Eagle Bay Advisors LLC bought a new position in MetLife during the 2nd quarter worth $28,000. Finally, Quintet Private Bank Europe S.A. acquired a new stake in shares of MetLife during the 3rd quarter worth $28,000. Institutional investors own 89.81% of the company’s stock.

Insider Transactions at MetLife

In other news, EVP Bill Pappas sold 27,000 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $72.27, for a total transaction of $1,951,290.00. Following the completion of the transaction, the executive vice president now directly owns 57,768 shares in the company, valued at $4,174,893.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Ramy Tadros sold 4,026 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $71.90, for a total transaction of $289,469.40. Following the completion of the transaction, the insider now directly owns 146,981 shares in the company, valued at $10,567,933.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Bill Pappas sold 27,000 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $72.27, for a total value of $1,951,290.00. Following the transaction, the executive vice president now owns 57,768 shares of the company’s stock, valued at $4,174,893.36. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.

MetLife Stock Performance

Shares of MET stock opened at $71.11 on Friday. The business’s 50-day moving average price is $71.12 and its 200-day moving average price is $66.77. MetLife, Inc. has a 12 month low of $48.95 and a 12 month high of $74.68. The firm has a market capitalization of $51.41 billion, a price-to-earnings ratio of 38.86, a PEG ratio of 0.53 and a beta of 1.04. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.53.

MetLife (NYSE:MET – Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The financial services provider reported $1.93 EPS for the quarter, missing analysts’ consensus estimates of $1.95 by ($0.02). MetLife had a net margin of 2.36% and a return on equity of 19.48%. The firm had revenue of $18.72 billion for the quarter, compared to analyst estimates of $18.07 billion. Equities research analysts forecast that MetLife, Inc. will post 8.71 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on MET shares. The Goldman Sachs Group raised MetLife from a “neutral” rating to a “buy” rating and increased their target price for the stock from $70.00 to $80.00 in a report on Monday, January 8th. Keefe, Bruyette & Woods increased their target price on MetLife from $82.00 to $87.00 and gave the stock an “outperform” rating in a report on Wednesday, April 10th. UBS Group reduced their target price on MetLife from $87.00 to $82.00 and set a “buy” rating on the stock in a report on Monday, February 5th. Wells Fargo & Company increased their target price on MetLife from $83.00 to $86.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Finally, Morgan Stanley raised their price objective on MetLife from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Monday, April 15th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.23.

Read Our Latest Stock Analysis on MET

MetLife Company Profile

(Free Report)

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.

Featured Articles

• Five stocks we like better than MetLife
• Business Services Stocks Investing
• MarketBeat Week in Review – 4/15 – 4/19
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit
• Comprehensive Analysis of PayPal Stock
• Best Stocks Under $5.00
• Intuitive Surgical Stock Can Trend Much Higher This Year

Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.